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Abstract
Background: To identify a novel therapeutic agent for hepatocellular carcinoma (HCC), for which no promising
therapeutic agent exists, we screened a panel of plants and found that Juniperus chinensis exhibited potential
antiangiogenic and anti-HCC activities. We further investigated the antiangiogenic and anti-HCC effects of the
active ingredient of J. chinensis extract, CBT-143-S-F6F7, both in vitro and in vivo.
Methods: A tube formation assay conducted using human umbilical vein endothelial cells (HUVECs) was first
performed to identify the active ingredient of CBT-143-S-F6F7. A series of angiogenesis studies, including HUVEC
migration, Matrigel plug, and chorioallantoic membrane (CAM) assays, were then performed to confirm the effects
of CBT-143-S-F6F7 on angiogenesis. The effects of CBT-143-S-F6F7 on tumor growth were investigated using a
subcutaneous and orthotopic mouse model of HCC. In vitro studies were performed to investigate the effects of
CBT-143-S-F6F7 on the cell cycle and apoptosis in HCC cells. Moreover, protein arrays for angiogenesis and
apoptosis were used to discover biomarkers that may be influenced by CBT-143-S-F6F7. Finally, nuclear magnetic
resonance analysis was conducted to identify the compounds of CBT-143-S-F6F7.
Results: CBT-143-S-F6F7 showed significantly antiangiogenic activity in various assays, including HUVEC tube
formation and migration, CAM, and Matrigel plug assays. In in vivo studies, gavage with CBT-143-S-F6F7 significantly
repressed subcutaneous Huh7 tumor growth in severe combined immunodeficient (SCID) mice, and prolonged the
survival of orthotopic Huh7 tumor-bearing SCID mice (a 40 % increase in median survival duration compared with
the vehicle-treated mice). Immunohistochemical staining of subcutaneous Huh7 tumors in CBT-143-S-F6F7-treated
mice showed a significantly decrease in the cell cycle regulatory protein cyclin D1, cellular proliferation marker
Ki-67, and endothelial marker CD31. CBT-143-S-F6F7 caused arrest of the G2/M phase and induced Huh7 cell
apoptosis, possibly contributing to the inhibition of HCC tumors. Protein array analysis revealed that several
angiogenic and antiapoptotic factors were suppressed in CBT-143-S-F6F7-treated Huh7 cells. Finally, five
compounds from CBT-143-S-F6F7 were identified.
Conclusions: According to these results, we report for the first time the antiangiogenic and anti-HCC activities of
CBT-143-S-F6F7, the active fractional extract of J. chinensis. We believe that CBT-143-S-F6F7 warrants further
evaluation as a new anti-HCC drug.
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Background
In 2012, hepatocellular carcinoma (HCC) was the sixth
most common cancer worldwide. Moreover, in 2012,
there were 746,000 liver-cancer-related deaths and
782,000 new HCC cases [1]. Many factors, such as
hepatitis B and C virus infection, chronic alcohol con-
sumption, aflatoxin-B1-contaminated food consumption,
fatty liver diseases, cirrhosis-inducing conditions, and
metabolic diseases, increase the risk of developing HCC
[1, 2]. Although many reliable methods could be used in
HCC diagnosis, treatments for HCC remain limited. In
patients with early-stage HCC, surgical resection and
liver transplantation are often used, and the 5-year sur-
vival rate can exceed 50 % [3, 4]. However, the recur-
rence rate in patients who underwent hepatectomy
exceeded 50 % in 2 years [5]. Moreover, for patients who
are unable to undergo hepatectomy, liver transplantation
could be considered, but is effective only for small, unre-
sectable HCCs in patients with cirrhosis [6]. For patients
with intermediate-stage HCC, transarterial chemoembo-
lization (TACE) is often performed. TACE results in an
improved 2-year survival rate compared with that of pa-
tients not suitable for resection, transplant, or radiofre-
quency ablation [7]. However, only an approximately
40 % complete response rate was reported after TACE
treatment [8]. In patients with advanced-stage HCC,
systemic chemotherapy could be considered but is not
recommended because of the low response rate [1]. Re-
cently, sorafenib, the first drug applied in targeted ther-
apy for HCC, was approved and drew considerable
attention. However, sorafenib, on average, could improve
the life expectancy of patients by only 2.8 months, which
is far from ideal [9]. Thus, developing novel therapeutics
for HCC is necessary.
HCC is usually an angiogenic tumor with a strong
angiogenesis-inducing ability [10, 11]. Angiogenesis and
vascularization can enhance tumor growth and progres-
sion by providing a higher nutrient and oxygen supply
than that provided through simple nutrient and oxygen
diffusion. In addition, angiogenesis and vascularization
enable tumor cells to escape into the circulation and
easily lodge in other organs, leading to metastatic tu-
mors [12, 13]. New vessels in tumors usually have abnor-
mal structures and functions, leading to an abnormal
tumor microenvironment. The abnormal tumor micro-
environment, including vascular hyperpermeability,
extracellular matrix remodeling, and endothelial cell ac-
tivation, may cause malignancies that are more aggres-
sive [11]. Because of these findings, new anticancer drug
development is targeted toward angiogenesis [14]. Many
factors, including vascular endothelial growth factor
(VEGF), platelet-derived growth factor (PDGF), basic
fibroblast growth factor (FGF), angiogenin, chemokine
(C-X-C motif ) ligand 16 (CXCL16), PDGF-AA, placental
growth factor (PlGF), and urokinase-type plasminogen
activator (uPA), contribute to tumor angiogenesis
[15–20]. For targeting these molecules, many drugs,
such as sorafenib, an oral multitargeted tyrosine kin-
ase inhibitor of VEGF receptor (VEGFR)-1, VEGFR-2,
and VEGFR-3 and PDGF receptors, have been devel-
oped and benefit HCC patients [21].
Juniperus chinensis, commonly known as Chinese juniper,
is a native and widely used ornamental plant in East Asian
countries. J. chinensis and plants of the same genus exhibit
many bioactivities, such as antimicrobial, antifungal, anti-
viral, antiinsect, antifertility, vasorelaxing, and antitumor
activities [22]. In in vitro studies, fresh J. chinensis leaf ex-
tracts exhibited cytotoxicity toward HeLa (human cervical
carcinoma) and HGC-27 (human gastric carcinoma) cells
[22]. Moreover, topically applying a J. chinensis extract
inhibited 7,12-dimethylbenz[a]anthracene (DMBA)- and
12-O-tetradecanoylphorbol-13-acetate (TPA)-induced pap-
illoma formation in mice [22]. Widdrol, an odorous
compound extracted from J. chinensis, inhibited the
in vitro growth of human colon adenocarcinoma HT29
cells [23]. The authors demonstrated that widdrol also
caused cell cycle arrest in the G1 phase, which is asso-
ciated with Chk2 induction, p53 phosphorylation, and
cyclin-dependent kinase (CDK) inhibitor p21 expres-
sion as well as cyclin E, CDK2, and retinoblastoma pro-
tein inhibition.
Although J. chinensis and its related compounds have
exhibited antitumor activities, the effects of J. chinensis
on the angiogenesis and progression of HCC remain
uninvestigated. In this study, the separation and identifi-
cation of the active ingredient of J. chinensis from an ex-
tract solution was guided using antiangiogenic and anti-
HCC activities. Through a series of in vitro and in vivo
preclinical experiments, we first demonstrated that the
active ingredient CBT-143-S-F6F7 exhibits antiangio-
genic and anti HCC activities. Moreover, we report for
the first time that gavage with CBT-143-S-F6F7 pro-
longed the survival of orthotopic HCC-bearing mice.
These results suggest that CBT-143-S-F6F7 is a potential
therapeutic agent for HCC.
Methods
Plant collection
The raw material of J. chinensis was collected in Hsinchu
City (GPS coordinate: 24°47'58.4"N 120°59'13.0"E). The
raw material was further authenticated as J. chinensis L.
var. sargentii Henry using internal transcribed spacers
(ITS) of nuclear ribosomal DNA, and the ITS sequence
had been deposited in the GenBank data base (Accession
Number: KX496336). A voucher specimen was deposited
at the plant collection bank of Industrial Technology Re-
search Institute (ITRI,Hsinchu, Taiwan).
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Preparation of CBT-143-S-F6F7 fraction from J. chinensis
Dried thin branches and leaves of J. chinensis L. var. sar-
gentii Henry were immersed in an 8- to 10-fold weight
of 95 % ethanol. Furthermore, for obtaining an extract
solution, the immersed plant materials were extracted at
the boiling point of the solvent for 1 h. The extract
solution was then filtered using filter paper and evap-
orated to dryness in vacuum. The extract was further
separated using a column (inner diameter: 5.5 cm;
length: 30 cm), which contained a 15-fold weight of
silica gel (0.040–0.063 mm, Silica gel 60, Merck), by
using an acetone:n-hexane mixture (from1:4 to 1:1) as
the eluent. After separation, the CBT-143-S-F6F7 frac-
tion was identified according to the results of a tube
formation assay of human umbilical vein endothelial
cells (HUVECs).
Cell culture
Five HCC cell lines, Huh7, Hep3B, PLC/PRF/5, SK-Hep-1,
and HepG2, were used. Huh7 was obtained from the
Japanese Collection of Research Bioresources. Hep3B,
PLC/PRF/5, and SK-Hep-1 were purchased from the
American Type Culture Collection. HepG2 cells and
HUVECs were obtained from the Bioresource Collec-
tion and Research Center, Taiwan. Hep3B cells were
maintained in Eagle’s minimum essential medium supple-
mented with 10 % heat-inactivated fetal bovine serum
(FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin.
The other HCC cells were grown in Dulbecco’s minimum
essential medium supplemented with 10 % FBS, 100 mM
nonessential amino acids, 100 U/mL penicillin, and
100 μg/mL streptomycin. All cells were cultured in a hu-
midified incubator at 37 °C and 5 % CO2. All reagents for
cell culture were purchased from Life Technologies
(Grand Island, NY, USA).
Animals
Female BALB/c (BALB/cAnNCrlBltw) and SCID (CB17/
Icr-Prkdcscid/CrlBltw) mice, aged 6–8 weeks and weigh-
ing 16–22 g, were purchased from BioLASCO Taiwan
Co. Ltd. (Ilan, Taiwan). One week before the study, all
mice were housed in conventional cages in the Animal
Laboratory for Biomedical Research (fully accredited by
the Association for Assessment and Accreditation of
Laboratory Animal Care in 2011) of Industrial Technol-
ogy Research Institute and allowed to acclimatize
and recover from shipping-related stress. Sterilized water
and food were provided ad libitum, and the mice
were housed in rooms maintained at 22 °C–26 °C
with 40–70 % humidity and a controlled 12-h light–dark
cycle. All experimental procedures for animal studies were
approved by the Institutional Animal Care and Use
Committees of ITRI (subcutaneous xenograft study:
ITRI-IACUC-2010-009 V1; Matrigel plug assay: ITRI-
IACUC-2010-058 V1; orthotopic model: ITRI-IACUC-
2011-020, and chorioallantoic membrane assay [CAM]:
ITRI-IACUC-2011-007).
HUVEC tube formation assay
Tube formation assay was performed as previously de-
scribed [24]. HUVECs were cultured in growth-factor-
reduced Matrigel (BD Biosciences, Franklin Lakes, NJ,
USA; 356231) and treated with different CBT-143-S-
F6F7 concentrations. The total length of the net struc-
ture was calculated using NIS element image analysis
software (Nikon; Agent: Lin Trading Co., Ltd. Taiwan).
By considering the total length of a net structure formed
from a group without drug treatment as 100 %, the state
of inhibition of HUVEC net structure formation elicited
by different drug treatments was analyzed.
HUVEC migration assay
The ability of CBT-143-S-F6F7 to inhibit HUVEC migra-
tion was observed using a BD transwell system. HUVECs
were seeded into an upper chamber in a medium without
FBS, and a medium with 10 % FBS was then added to a
lower chamber as an attractant. After 24 h, the transwell
was collected, and the migrating cells on the lower side of
membrane were stained with crystal violet to facilitate
observation.
Matrigel plug assay
Matrigel (BD Biosciences, 354234) was mixed with PBS
in a 9:1 ratio for mock control or 500 ng/mL FGF-b
(Peprotech, USA, 100-18B) and 500 ng/mL VEGF (R&D,
USA, 293-VE-500) for vehicle control. For studying anti-
angiogenesis, different CBT-143-S-F6F7 concentrations
were added to Matrigel mixed with FGF-b and VEGF.
Fourteen days after subcutaneous Matrigel injection,
BALB/c mice were sacrificed, Matrigel plugs were col-
lected, and hemoglobin in the plugs was quantified
using a QuantiChrom Hemoglobin Assay Kit (BioAssay
Systems, USA, DIHB-250).
CAM assay
The embryos of unhatched eggs from specific-pathogen-
free white Leghorn chicken were placed laterally in an
incubator (37 °C, relative humidity: 55–60 %). On day 4
of the incubation period, 2.5 mL of albumin was drawn
from the eggs using a 20-G needle, and a fake air cham-
ber was constructed on the embryo. Subsequently, the
needle hole and fake air chamber were sealed using 3 M
breathable tape. On day 7, CBT-143-S-F6F7 was dis-
solved with dimethyl sulfoxide (DMSO) and diluted with
PBS. For each group, including a vehicle group, the final
DMSO concentration was 1 %. CBT-143-S-F6F7 was
loaded on 6-mm-diameter Circular Advantec filter paper
(Toyo Roshi Kaisha, Ltd., Tokyo, Japan), and the paper
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was placed on the CAM. On day 9, the CAM was photo-
graphed using the SZX16 dissecting microscope (Olympus,
Japan). By using the filter paper as the center, four concen-
tric circles were marked on the photograph (diameters of
7, 8, 9, and 10 mm; total circumference of the four circles
was 106.8 mm, and total circumference represented the re-
gion near the filter paper) [25]. The amount of vessels
crossing the concentric circles (the vascular density index
or VDI) was used to evaluate the state of angiogenesis. The
VDI for the same photograph was determined by three
people, and the mean VDI was adopted.
Cell viability assay
HCC cells were seeded in 96-well plates at 104 cells/well
and treated with CBT-143-S-F6F7 for 48 h. The cells
were then exposed to a culture medium containing
0.5 mg/mL of (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide) (MTT) (Sigma–Aldrich, St. Louis,
MO, USA). After 2–3 h, DMSO was added to dissolve
the resulting formazan. For each solution, the optical
density at 570 nm was measured using a microplate
spectrophotometer (SpectraMax M5, Molecular Devices,
USA). Cell viability was calculated as follows: viability
(%) = A570 of treated cells/A570 of control cells × 100.
The half maximal inhibitory concentration (IC50) was es-
timated using GraFit software.
In vivo subcutaneous tumor model
Huh7 cells (3 × 106) were suspended in 100 μL of PBS
with 25 % Matrigel and subcutaneously implanted into
the right flank of female SCID mice. Tumors were mea-
sured three times per week by using calipers, and tumor
volume was calculated as follows: tumor volume (V)
= (LS2)/2 (L, longest diameter, mm; S, shortest diameter,
mm). Treatments were initiated when the tumor volume
reached 150–200 mm3. The mice were randomly
grouped into groups of six. CBT-143-S-F6F7 was dis-
solved in a formulation of 10 % 1-Methyl-2-pyrrolidone
(M6762, Sigma–Aldrich), 20 % Cremophor EL (C5135,
Sigma–Aldrich), and 70 % saline. CBT-143-S-F6F7 was
administered daily through gavage at a dose of 100 mg/
kg body weight for 21 days. The tumor volume and body
weight of the mice were monitored. The antitumor activ-
ity of treatments was represented by the percentage of
tumor growth inhibition (TGI), which was calculated as
follows: [1 − (final tumor volume – initial tumor volume
for treated group)/(final tumor volume – initial tumor
volume for vehicle group)] × 100. Data are represented as
the mean ± standard error of the mean (SEM).
In vivo orthotopic tumor model
Mice were anesthetized with a mixed solution [40 mg/kg
body weight of Zoletil 50 (Virbac, France) and 10 mg/kg
body weight of Xylazine (Rompun 2 % injection,
Bayer, German)] through intraperitoneal (i.p.) injec-
tion. Through an upper middle abdominal cavity inci-
sion, the left lateral lobe of the liver was exposed.
Huh7 cells (1 × 106) were suspended in 50 μL of PBS
with 50 % Matrigel and were implanted into the left
lateral lobe of the liver by using an insulin syringe
with a needle (29 G X1/2", Terumo, Shibuya, Japan),
and the wound was then closed using an interrupted
suture and Autoclip wound closing system (59043,
Stoelting, USA). Seven days after the implantation,
CBT-143-S-F6F7 treatment (100 mg/kg through oral
administration) was initiated and proceeded for
42 days. The body weight of the mice was monitored
twice a week, and blood samples were collected from
the facial vein. Survival analysis was conducted using
the Kaplan–Meier method and GraphPad Prism® was
used for generating survival curve and performing re-
lated statistics. The human α-fetoprotein (AFP) level
in mouse serum was determined using AFP ELISA
(IB19102, IBL-America, USA).
Immunohistochemistry analysis
After the mice were sacrificed, tumor tissues were
fixed in formalin and embedded in paraffin as tumor
sections for further analysis. Immunostaining was
completed using an Autostainer Link 48 system
(Dako, Glostrup, Denmark). The antihuman Ki-67
(IS-626, Dako), antihuman cyclin D1 (1:500, IS-083,
Dako), and anti-CD31 antibodies (LS-B1932, Lifespan,
USA) were used for immunostaining. Five fields
(100 × 100 μm2) of each tumor sample were randomly
selected, and the percentages of Ki-67-positive and
cyclin D1-positive cells were calculated to evaluate
cell proliferation in tumor tissues. For quantifying
CD31-positive cells, ten fields of each tumor sample
were randomly selected. The results are presented as
the mean ± standard deviation (SD).
Flow cytometry for cell cycle analysis and annexin V
staining
For cell cycle analysis, Huh7 cells were seeded in 6-well
plates at 2 × 105 cells/well and treated with CBT-143-S-
F6F7 for 48 h. The cells were collected through trypsiniza-
tion and fixed overnight in 70 % ethanol at −20 °C. The
fixed cells were then washed with PBS. For measuring
DNA content, the cells were stained with a propidium
iodide (PI) solution [2 μg/mL PI, 200 μg/mL RNase A,
and 0.1 % (w/v) Triton X-100] (Sigma–Aldrich) and incu-
bated in the dark for 30 min at 37 °C. DNA content was
determined using a FACScan flow cytometer (BD Biosci-
ences). Data were analyzed using ModFit LT software
(Verity Software House, USA).
For apoptosis analysis by using PI and annexin V stain-
ing, Huh7 cells were seeded in 6-well plates at 2 × 105
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cells/well and treated with CBT-143-S-F6F7 for 48 h.
The cells were collected through trypsinization, and PI
and annexin V staining was then conducted using an
annexin V–fluorescein isothiocyanate apoptosis detec-
tion kit (Strong Biotech Corp., Taipei, Taiwan).
Protein array analysis
Huh7 cells were treated with CBT-143-S-F6F7 for 48 h,
and the cell lysate and condition medium were collected
and analyzed using the Proteome Profiler Human Apop-
tosis Array Kit (R&D, ARY009) and Proteome Profiler
Human Angiogenesis Array Kit (R&D, ARY007), respect-
ively. The operating procedures were performed according
to instructions in the user manual. Chemoluminescent
signals were monitored using the BioSpectrum 610 im-
aging system (UVP, USA) and analyzed using ImageJ
software.
Identification of active compounds from CBT-143-S-F6F7
CBT-143-S-F6F7 was further purified using a fast pro-
tein liquid chromatography (FPLC) system, which was
conducted using GE Healthcare Unicorn 5.1 controller
equipped with P-900 pump, superloop 50 mL, UV-900
monitor detector and Frac-920 fraction collector. FPLC
was performed with Toyo Pearl® HW-40S column (inner
diameter: 3 cm; length: 30 cm; flow rate: 5 mL/min) and
then eluted with 95 % ethanol to yield five fractions.
Fraction 2 was further purified using a column (inner
diameter: 2 cm; length: 20 cm) packed with 100 g silica
gel (0.015-0.040 mm, Silica gel 60, Merck) and then
eluted with Ethyl acetate/n-hexane (1:5) at flow rate of
10 mL/min to yield deoxypodophyllotoxin, acetyl podo-
phyllotoxin and yatein. Fraction 3 was further purified
using a column (inner diameter: 2 cm; length: 25 cm)
packed with 120 g silica gel (0.015-0.040 mm, Silica gel
60, Merck) and eluted with ethyl acetate/n-hexane (1:3)
at flow rate of 10 mL/min to get savinin. Fraction 4 was
further purified using a column (inner diameter: 2 cm;
length: 25 cm) packed with 120 g silica gel (0.015-
0.040 mm, Silica gel 60, Merck) and then eluted with
ethyl acetate/n-hexane (1:3) at flow rate of 10 mL/min
to obtain oxohinokinin. The structures of these com-
pounds were identified using nuclear magnetic reson-
ance (NMR) analysis. 1H (600 MHz) and 13C (150 MHz)
NMR spectra, DEPT, 1H-1H COSY, NOESY, HSQC, and
HMBC experiments were recorded by a varian unity
inova 600 NMR spectrometer at room temperature.
Chemical shifts were reported in δ units and coupling
constants (J) in Hz.
To determine the content of oxohinokinin, savinin, deox-
ypodophyllotoxin, acetyl podophyllotoxin, and yatein in
CBT-143-S-F6F7, high performance liquid chromatog-
raphy (HPLC) was conducted by using a Waters system
(Waters 600E controller and Waters 717 plus autosampler)
equipped with 996 photodiode array (PDA) detector
(Waters, 2998). HPLC was performed by using a Cos-
mosil 5C18-MS-II C-18 reversed phase column
(250 mm x 4.6 mm, 5 μm diameter particles) and the
flow rate is 0.8 mL/min. Eluents in reservoirs A-C were as
follows: 0.1 % phosphoric acid in water (A), acetonitrile
(B), methanol (C). Delivery programs f linear gradient are
A/B/C = 65/25/10 to A/B/C = 25/60/15 for 60 min. UV
absorption spectra were recorded at 280 nm.
Statistical analysis
All experimental data are expressed as the mean ± SD,
unless otherwise stated. The significance of differences
between groups was analyzed using the Student’s t test.
P < 0.05 was considered statistically significant.
Results
CBT-143-S-F6F7 is an active ingredient of J. chinensis
extract inhibiting angiogenesis
For identifying new drugs that can inhibit angiogenesis,
a tube formation assay was performed using HUVECs to
screen a panel of extracts from different plants. To
quantify the net structure of HUVECs, the total length
of the net structure was calculated using NIS element
image analysis software. We observed that the crude
extract from J. chinensis L. var. sargentii Henry, named
CBT-143-S, strongly inhibited tube formation in HUVECs,
and the IC50 was 221 ng/mL (data not shown). To
determine the active ingredient of CBT-143-S, differ-
ent CBT-143-S fractions were separated and collected
using a silica gel column. Among these fractions, the
fraction CBT-143-S-F6F7 strongly inhibited tube for-
mation in HUVECs (data not shown and Fig. 1a).
Moreover, the IC50 of CBT-143-S-F6F7 in inhibiting
tube formation in HUVECs was 12.3 ng/mL (Fig. 1b),
which is 20.3-fold lower than that of CBT-143-S. No
cytotoxicity was observed in the CBT-143-S-F6F7-treated
group (data not shown). According to the aforementioned
data, CBT-143-S-F6F7 was identified as the active ingredi-
ent of CBT-143-S and its antiangiogenic efficacy was fur-
ther investigated using different models. In addition to
tube formation inhibition in HUVECs, CBT-143-S-F6F7
also decreased the number of HUVECs on lower side of
membrane in a transwell study (Fig. 1c), suggesting CBT-
143-S-F6F7 also suppressed HUVEC migration. No cyto-
toxicity was evident in the CBT-143-S-F6F7-treated group
(data not shown). According to these in vitro results,
CBT-143-S-F6F7 showed potential inhibitory activities
against the tube formation and migration of HUVECs.
To determine whether CBT-143-S-F6F7 can suppress
angiogenesis in vivo, a Matrigel plug assay was per-
formed. The Matrigel was mixed with VEGF, and FGFb
exhibited a red color, indicating vascularization in Matri-
gel plugs (Fig. 1d). In the presence of CBT-143-S-F6F7,
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the Matrigel plugs showed less red color than the vehicle
group did, indicating no vascularization in the Matrigel
plugs (Fig. 1d). Hemoglobin content in the plugs was
measured to quantify the degree of angiogenesis. The
hemoglobin content in the Matrigel plugs of the vehicle
group was 52.64 ± 26.18 mg/dL. The hemoglobin con-
tents in the Matrigel plugs of 30 μg/mL and 100 μg/mL
CBT-143-S-F6F7-treated groups were 56.70 ± 5.58 mg/dL
and 25.08 ± 9.59 mg/dL, respectively. This result suggested
that CBT-143-S-F6F7 inhibited neovascularization in the
Matrigel plug assay (Fig. 1e).
To confirm the in vivo antiangiogenic activity of CBT-
143-S-F6F7, a CAM assay was performed. CBT-143-S-
F6F7 was loaded onto filter paper at two doses (10 μg
and 25 μg per embryo), and the filter paper was placed
on the CAM. After treatment for 48 h, the CAM was
photographed and the degree of angiogenesis was quan-
tified using the VDI, as described in Subsection of ma-
terial and methods. The degree of vascularization was
lower in the CBT-143-S-F6F7-treated group than in the
vehicle-treated group (Fig. 1f ). The VDI of the vehicle
group was 163.7 ± 22.7 and that of the CBT-143-S-F6F7-
treated group was 119.1 ± 30.1 and 149.3 ± 40.3 at doses
of 10 μg and 25 μg per embryo, respectively. These re-
sults suggested that CBT-143-S-F6F7 reduced the
vascularization of the CAM. In summary, CBT-143-S-
F6F7 was the active ingredient of the J. chinensis extract
(CBT-143-S) and inhibited angiogenesis both in vitro
and in vivo.
CBT-143-S-F6F7 inhibits HCC cell growth
According to the aforementioned data, we demonstrated
that CBT-143-S-F6F7 was the active ingredient of the J.
chinensis extract that inhibited angiogenesis, and J. chi-
nensis extracts inhibit cancer cell growth [22]. We then
investigated whether CBT-143-S-F6F7 inhibited the
growth of HCC cells, namely Huh7, Hep3B, HepG2,
PLC/PRF/5, and SK-Hep-1 cells. After CBT-143-S-F6F7
treatment for 48 h, the growth-inhibiting effect of CBT-
143-S-F6F7 on HCC cells was evaluated using an MTT
assay and the IC50 of CBT-143-S-F6F7 for different HCC
cell types was obtained (Table 1). Among the cell types,
Hep3B cells had the lowest sensitivity to CBT-143-S-F6F7.
Hep3B cells also have been reported to show lower sensi-
tivity to curcumin and sorafinib when compared with
other HCC cells [26, 27]. Checkpoint kinase 1 (Chk1) and
growth arrest DNA damage-inducible gene 45 gamma
(GADD45γ) have been reported to play roles in this
phenomenon respectively [26, 27]. However, because these
HCC cell lines inherit different gene heterogeneity, why
Hep3B cells had the lowest sensitivity to CBT-143-S-F6F7
may be complicated.
CBT-143-S-F6F7 suppresses tumor growth in vivo
Because CBT-143-S-F6F7 suppressed angiogenesis and
HCC cell growth in vitro, we investigated the in vivo
effects of CBT-143-S-F6F7 on Huh7 tumor growth. For
21 days, we administered CBT-143-S-F6F7 through
gavage (100 mg/kg/day) to subcutaneous Huh7
tumor-bearing SCID mice. After the treatment, the
mean tumor volume of CBT-143-S-F6F7-treated mice
was 1081 ± 207 mm3 and that of vehicle-treated mice
was 1807 ± 240 mm3 (Fig. 2a). Tumor growth was sig-
nificantly repressed in CBT-143-S-F6F7-treated mice
compared with vehicle-treated mice (P = 0.04). After
21 days of exposure to CBT-143-S-F6F7, the TGI in
tumor-harboring mice was 42 % ± 11 %. During CBT-143-
S-F6F7 treatment, the mean body weight of CBT-143-S-
F6F7-treated mice was not significantly different from that
of vehicle-treated mice and no cytotoxicity was observed
(Fig. 2b). In summary, these results showed that CBT-143-
S-F6F7 suppressed tumor growth without severe adverse
effects in Huh7 tumor-bearing mice.
The expression of the cell proliferation markers Ki67
and cyclin D1 in Huh7 tumor tissues was analyzed using
immunohistochemical analysis (Fig. 3a). In immunohis-
tochemical staining for Ki-67, the percentage of Ki-67-
positive cells in CBT-143-S-F6F7-treated tumors was
48.8 ± 5.3 %, which is significantly lower than that in
vehicle-treated tumors (58.6 % ± 4.7 %, P < 0.05, Fig. 3b).
Similarly, the percentage of cyclin D1-positive cells in
CBT-143-S-F6F7-treated tumors was 48.0 % ± 1.4 %,
which is significantly lower than that in vehicle-treated
Table 1 CBT-143-S-F6F7 inhibited the growth of different HCC
cells
IC50 (μg/mL)
Cell line Huh7 Hep3B HepG2 PLC/PRF/5 SK-Hep-1
CBT-143-S-F6F7 <0.1 15.71 <0.1 <0.1 <0.1
(See figure on previous page.)
Fig. 1 CBT-143-S-F6F7 inhibited angiogenesis. a CBT-143-S-F6F7 showed concentration-dependent inhibition the tube formation of HUVECs. b The net
structure of HUVECs and the related total length of the net structure of HUVECs suppressed by CBT-143-S-F6F7 concentration-dependently. c CBT-143-S-
F6F7 suppressed HUVEC migration by using a transwell assay. When treated with CBT-143-S-F6F7, less HUVECs stained with crystal violet were observed on
lower side of membrane. d CBT-143-S-F6F7 inhibited angiogenesis in a Matrigel plug assay (Formation of red color in a Matrigel plug indicate vascular
formation.) e CBT-143-S-F6F7 concentration-dependently inhibited the content of hemoglobin in the Matrigel plugs.*:P< 0.05 vs. vehicle group.
f CBT-143-S-F6F7 concentration-dependently suppressed vessel formation in a CAM assay. The quantitative analysis of vessel formation was demonstrated
using VDI as mentioned in Methods. *:P< 0.05 vs. vehicle group
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tumors (59.4 % ± 5.7 %, P < 0.05, Fig. 3c). These results
collectively showed that CBT-143-S-F6F7 strongly
suppressed Ki-67 and cyclin D1 expression in tumors,
evidencing that CBT-143-S-F6F7 can inhibit in vivo
tumor cell proliferation.
Moreover, to determine whether CBT-143-S-F6F7 can
inhibit angiogenesis in tumors, we performed CD31 im-
munohistochemical staining of Huh7 tumors (Fig. 3a)
because CD31 is a vascular endothelial cell marker. The
mean number of CD31-positive cells per 100 × 100 μm2
ba
*
Days after Huh7 inoculation Days after Huh7 inoculation
Fig. 2 CBT-143-S-F6F7 suppressed the growth of subcutaneous Huh7 tumors in SCID mice. a CBT-143-S-F6F7 (100 mg/kg/day) suppressed the
growth of Huh7 tumor. *:P < 0.05 vs. vehicle group. b There was no statistical difference in the body weights of either group of mice throughout




40 µm 40 µm










Fig. 3 CBT-143-S-F6F7 inhibited Ki67, cyclin D1, and CD31 expression in a Huh7 tumor. a Immunohistochemical staining was performed to
examine Ki67, cyclin D1, and CD31 expression. b The percentage of Ki67 positive cells per field. c The percentage of cyclin D1-positive cells per
field. d The number of CD31-positive cells per field. Data was expressed as the mean ± SD per field. *: P < 0.05 compared with vehicle tumors,
**: P < 0.01 compared with vehicle tumors
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in the vehicle group was 4.3 ± 1.2 and that in the
CBT-143-S-F6F7-treated group was 1.4 ± 0.5. CBT-
143-S-F6F7 significantly reduced the number of vas-
cular endothelial cells (CD31-positive cells) in tumors
(P < 0.05, Fig. 3d). In summary, CBT-143-S-F6F7 sup-
pressed Huh7 tumor cell proliferation and reduced the
number of vascular endothelial cells in Huh7 tumors.
CBT-143-S-F6F7 prolongs the survival of orthotopic HCC-
tumor-bearing mice
According to the aforementioned data, CBT-143-S-F6F7
strongly suppressed subcutaneous HCC tumor growth
in a mouse xenograft model; however, a subcutaneous
HCC tumor is considerably different in the real physio-
logical environment of HCC in the liver. To further
evaluate the antitumor activity of CBT-143-S-F6F7, we
used an orthotopic HCC model in SCID mice. Seven
days after the orthotopic implantation of Huh7 cells in
the liver, CBT-143-S-F6F7 was administered daily
through gavage until the experiment ended. The survival
curves of vehicle- and CBT-143-S-F6F7-treated mice
with orthotopic Huh7 tumors are shown in Fig. 4a. The
median survival duration of the CBT-143-S-F6F7-treated
group was 70 days, which is significantly longer than
that of the vehicle-treated group (50 days). This result
showed that CBT-143-S-F6F7 prolonged the survival of
orthotopic HCC-tumor-bearing mice.
Because AFP is a surrogate biomarker in HCC diagnos-
tics, we performed AFP ELISA to monitor the concentra-
tion of AFP, used as an indicator for monitoring
orthotopic HCC tumor growth, in orthotopic HCC-
tumor-bearing mice. On day 21 after tumor implant-
ation, the AFP concentration in the vehicle group was
1,752,948 ± 1,338,693 ng/mL and that in the CBT-143-
S-F6F7-treated group was 1,312,510 ± 944,306 ng/mL
(P = 0.24, Fig. 4b). Moreover, on day 35 after tumor
implantation, the AFP concentration in the vehicle-treated
group was 4,780,122 ± 2,929,242 ng/mL and that in
the CBT-143-S-F6F7-treated group was 2,705,733 ±
1,463,381 ng/mL (P = 0.06, Fig. 4c). At both instances,
the AFP concentration in the CBT-143-S-F6F7-treated
group was lower than that in the vehicle-treated
group; however, the reduction in the AFP concentration
was not statistically significant. Nevertheless, the P value
decreased from 0.24 to 0.07 from days 21 to 35, indicating
















AFP level on day 21 
P=0.039
Vehicle CBT143-S-F6F7








Days after Huh7 inoculation
Treatment
c
Fig. 4 CBT-143-S-F6F7 prolonged the survival of orthotopic Huh7-tumor-bearing mice. a Survival curves of orthotopic Huh7- tumor-bearing mice
and median survival duration. b Serum AFP concentration at days 21 after implanting Huh7 cells. c Serum AFP concentration at days 35 after
implanting Huh7 cells. Vehicle group, n = 10; CBT-143-S-F6F7-treated group, n = 7
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concentration was more statistically significant in this
period. In summary, CBT-143-S-F6F7 suppressed orthoto-
pic Huh7 tumor growth and prolonged the survival of
orthotopic Huh7 tumor-bearing mice.
CBT-143-S-F6F7 causes G2/M arrest and induces
apoptosis in HCC cells
To identify factors causing the growth inhibitory effect
of CBT-143-S-F6F7 on liver cancer cells, we investigated
the effect of CBT-143-S-F6F7 on the HCC cell cycle.
Huh7 cells were treated with various CBT-143-S-F6F7
concentrations for 48 h, and the cell cycle state was de-
termined using PI staining and flow cytometry. Obvious
G2/M arrest was observed in CBT-143-S-F6F7-treated
Huh7 cells (Fig. 5a). The number of G2/M-arrested cells
increased after the CBT-143-S-F6F7 concentration in-
creased. These data suggest that CBT-143-S-F6F7-in-
duced inhibition of cell cycle progression could be a
molecular event associated with the growth inhibitory
effect of CBT-143-S-F6F7 in HCC cells.
To determine whether CBT-143-S-F6F7 can induce
Huh7 cell apoptosis, PI and annexin V staining were per-
formed for monitoring the apoptotic status of CBT-143-
S-F6F7-treated Huh7 cells. More early apoptotic cells
were detected among CBT-143-S-F6F7-treated Huh7
cells, and the percentages of early apoptotic cells were
3.27 %, 6.6 %, and 8.23 % for 0.01, 0.1, and 1 μg/mL
CBT-143-S-F6F7, respectively (Fig. 5b). These results
suggested that CTB-143-S-F6F7 arrested the cell cycle in
the G2/M phase and induced apoptosis in Huh7 cells,
possibly contributing to the growth inhibitory effect of
CBT-143-S-F6F7 in HCC cells.
Protein array analysis of CBT-143-S-F6F7-treated Huh7
cells
The effects of CBT-143-S-F6F7 on the expression of
angiogenic and apoptotic factors in Huh7 cells were
studied at the protein level by using the Proteome Pro-
filer Human Angiogenesis Array and Proteome Profiler
Human Apoptosis Array (Additional file 1: Figure S1).
Figure 6a shows changes in the angiogenesis-related
protein expression profile and corresponding protein ex-
pression quantified using densitometric analysis after the
incubation of Huh7 cells with CBT-143-SF6F7 for 48 h.
Five angiogenic factors, angiogenin, CXCL16, PDGF-AA,
PlGF, and uPA, were obviously suppressed after CBT-143-
SF6F7 treatment, and the results regarding relative expres-
sion are shown in Fig. 6a. Changes in the apoptosis-
a
0.01 µg/ml 0.1 µg/ml 1 µg/mlVehicle
CBT-143-S-F6F7












0.1 µg/mL 1 µg/mL0.01 µg/mL
4.6%
3.27%
Fig. 5 CBT-143-S-F6F7 caused G2/M arrest and induced Huh7 cell apoptosis. a CBT-143-S-F6F7 caused G2/M arrest in Huh7 cells in analysis of cell
cycle by PI staining for DNA content. b The apoptotic status of Huh7 cells was monitored using PI and annexin V staining
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related protein expression profile are shown in Fig. 6b,
and four antiapoptotic factors, namely B-cell lymphoma 2
(Bcl-2), cellular inhibitor of apoptosis 1 (cIAP-1), cellular
inhibitor of apoptosis 2 (cIAP-2), and Claspin, were sup-
pressed by CBT-143-S-F6F7 treatment. The quantified
results are shown as the relative expression in Fig. 6b.
Further confirmation of these results and the detailed
mechanisms is in progress.
Identification of compounds from CBT-143-S-F6F7
According to the aforementioned results, CBT-143-S-
F6F7 considerably suppressed angiogenesis and HCC
cell growth both in vitro and in vivo. We identified the
possible active compounds in CBT-143-S-F6F7. After a
series of purification and isolation steps, we identified
five compounds from CBT-143-S-F6F7, and their struc-
tures were identified by using nuclear NMR analysis and
are shown in Fig. 7a. According to the literature, these
five compounds are oxohinokinin, savinin, deoxypodo-
phyllotoxin, acetyl podophyllotoxin, and yatein. The
contents of these compounds from CBT-143-S-F6F7
were determined using high-performance liquid chroma-
tography (Fig. 7b). The contents of deoxypodophyllo-
toxin (122.81 mg/g) and yatein (150.74 mg/g) were the
highest in CBT-143-S-F6F7. For determining the active
compounds of CBT-143-S-F6F7, mass purification and
functional studies of these compounds are in progress.
Discussion
HCC is the sixth most common cancer worldwide in
2012 [1]. HCC patients usually have a poor prognosis
because of the advanced stage of HCC at the time of ini-
tial diagnosis, unsuitability of patients for surgery, and
frequent recurrence and resistance to conventional ther-
apy [3, 4]. HCC is usually an angiogenic cancer with a
strong angiogenesis-inducing ability, which could cause
more aggressive malignancies [10, 11]. Accordingly, new
anticancer drug development is targeted toward angio-
genesis [14]. Although many drugs for targeted therapy
for HCC have been developed, no promising results have
been reported. For example, sorafenib, the first targeted
therapy drug for HCC, shows antiangiogenic activities.
However, sorafenib only slightly improved life expect-
ancy [9]. To provide an alternative HCC treatment, we
used herbal extracts to identify new therapeutic agents
targeting angiogenesis. After screening a panel of herb
extracts by using a tube formation assay, we identified
the major active ingredient of J. chinensis extract, CBT-
143-S-F6F7, which showed antiangiogenic activity in in
vitro and in vivo models, including the inhibition of tube
formation and migration of HUVECs and suppression of
vascularization in CAM and Matrigel plug assays (Fig. 1).
CBT-143-S-F6F7 also repressed the growth of subcuta-
neous Huh7 tumors in SCID mice (Fig. 2a) and reduced
the expression of the cell cycle regulatory protein cyclin
D1, cellular proliferation marker Ki-67, and endothelial
marker CD31, according to immunohistochemical stain-
ing of subcutaneous HCC tumors (Fig. 3). We also dem-
onstrated for the first time that CBT-143-S-F6F7
prolonged the survival of orthotopic HCC-tumor-
bearing SCID mice (Fig. 4). Regarding safety, compared
with the mice in the vehicle group, mice continually ad-
ministered CBT-143-S-F6F7 for 21 days did not show a
loss of body weight (Fig. 2b) or other side effects, sug-
gesting that CBT-143-S-F6F7 has no significant toxicity
in mice. CBT-143-S-F6F7 inhibited the growth of several
a b
Fig. 6 Angiogenesis and apoptosis array analysis of CBT-143-S-F6F7-treated Huh7 cells. a Five angiogenesis-related factors were down-regulated
when treated with CBT-143-S-F6F7. b four apoptotic factors were down-regulated when treated with CBT-143-S-F6F7. The density of each spot
was quantified using ImageJ, and the expression of each protein was normalized with that of a vehicle-treated sample
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different HCC cells (Table 1); this inhibition was associ-
ated with cell cycle arrest in the G2/M phase and apop-
tosis induction in Huh7 cells (Fig. 5). Taken together,
these results demonstrate that CBT-143-S-F6F7 showed
antiangiogenic and anti-HCC activities and could be a
potential candidate for HCC therapy.
J. chinensis L. extracts can inhibit the growth of some
cancer cell types, and topically applying the extracts
inhibited DMBA- and TPA-induced papilloma formation
in mice [22]. Here, we first report the antiangiogenic
and anti-HCC activities of CBT-143-S-F6F7, an active
ingredient of a J. chinensis L. extract, in in vitro and in
vivo studies. Most importantly, we demonstrated that or-
ally administering CBT-143-S-F6F7 suppressed the
growth of subcutaneous HCC tumors and prolonged the
survival of orthotopic HCC-tumor-bearing SCID mice.
The anti-HCC activity of CBT-143-S-F6F7 could be at-
tributed to its effects of angiogenesis inhibition, HCC
cell growth suppression, and apoptosis induction in
HCC cells. The antiangiogenic effect of CBT-143-S-F6F7
was demonstrated in IHC analysis of a subcutaneous
HCC tumor, and CBT-143-S-F6F7 reduced the number
of vascular endothelial cells (CD31+ cells), leading to de-
creased angiogenesis and nutrient supply and tumor
growth inhibition. Moreover, CBT-143-S-F6F7 inhibited
HCC cell growth (Table 1) by arresting the cell cycle in
the G2/M phase (Fig. 5a) and inducing apoptosis
(Fig. 5b). However, the effect of CBT-143-S-F6F7-in-
duced apoptosis was weaker than that of CBT-143-S-
F6F7-induced cell cycle arrest in the G2/M phase (Fig. 5),
possibly suggesting that cell cycle arrest in the G2/M
phase may be the main mechanism of CBT-143-S-F6F7
in inhibiting HCC cell growth. Tumor growth inhibition
was demonstrated in the IHC analysis of a subcutaneous
HCC tumor, and CBT-143-S-F6F7 reduced the expres-
sion of the cell proliferation markers Ki67 and cyclin D1
[28, 29]. Collectively, by inhibiting the angiogenic














































a Oxohinokinin Savinin Deoxypodophyllotoxin
Acetyl podophyllotoxin Yatein
Fig. 7 Identification of compounds from CBT-143-S-F6F7. a Compounds obtained from CBT-143-S-F6F7. b The content of each identified
compound in CBT-143-S-F6F7 was determined using high-performance liquid chromatography
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vivo antiHCC effects. Moreover, many anticancer drugs,
such as paclitaxel, cause G2/M arrest and induce apop-
tosis, and many of them are tubulin-targeting drugs [30].
In the present study, CBT-143-S-F6F7 showed similar
effects, suggesting that tubulin may be a CBT-143-S-
F6F7 target; however, additional studies are required for
verifying this assumption.
CBT-143-S-F6F7 has many advantages as a new thera-
peutic agent for HCC. For example, CTB-143-S-F6F7
could be orally administrated to perform various anti-
cancer activities. Presently, many anticancer drugs,
including small molecules and protein drugs, are admin-
istrated through infusion, which can be performed only
by well-trained medical personnel. Treatment through
the oral route is clinically convenient and suitable for
cancer patients who usually require prolonged treatment
regimens [31]. CBT-143-S-F6F7 is advantageous for clin-
ical use in the future. Moreover, compared with normal
cells, cancer cells accumulate many distinct genetic and
epigenetic alterations, which affect multiple regulatory
pathways within the cells and cause distinct malignant
phenotypes. For treating cancer, multitarget drugs are
believed to yield more positive outcomes than single-
target drugs do. Herbal medicines have drawn more
attention recently because of their mixed components,
which may have various bioactivities [32]. According to
the aforementioned results, CBT-143-S-F6F7 exhibits
both antiangiogenic and anticancer activities, reflecting
the trend of developing multitarget drugs, and could
prove advantageous in treating cancers in the future.
To determine the possible mechanism through which
CBT-143-S-F6F7 inhibits angiogenesis and induces
apoptosis, the Proteome Profiler Human Angiogenesis
Array and Proteome Profiler Human Apoptosis Array
were used for identifying CBT-143-S-F6F7-targeted an-
giogenic and apoptotic factors. Compared with vehicle
treatment, we found that five angiogenic factors, angio-
genin, CXCL16, PDGF-AA, PlGF, and uPA, were
suppressed by CBT-143-S-F6F7 treatment in Huh7 cells.
Angiogenin is usually upregulated in various cancers
such as colorectal carcinoma, breast cancer, and HCC
[33], and it promotes angiogenesis and induces cancer
proliferation [16]. CXCL16 and its receptor CXCR6 are
closely associated with endothelial progenitor cell re-
cruitment and angiogenesis [17]. PDGF-AA is an angio-
genic factor, responsible for the failure of reinitiated
interferon (IFN)-α treatment when HCC recurs after the
initial IFN-α treatment [18]. PlGF, a VEGF family mem-
ber, is an attractive drug candidate for angiogenesis in-
hibition in HCC [19]. uPA is a well-known angiogenic
factor in urokinase-mediated plasminogen activation
system for modifying the extracellular matrix and is highly
involved in angiogenesis [20]. CBT-143-S-F6F7 may in-
hibit angiogenesis by suppressing these angiogenic factors.
Apoptosis array analysis showed that Bcl-2, cIAP-1,
cIAP-2, and Claspin were suppressed in CBT-143-S-
F6F7-treated Huh7 cells. Bcl-2 protein, an antiapoptotic
factor, is often deregulated in cancer and has become a
promising anticancer drug target [34]. cIAP-1 and cIAP-2
are inhibitor of apoptosis protein members, which con-
tribute to apoptosis resistance and are typically overex-
pressed in HCC tissues [35]. Under apoptotic conditions,
Claspin is cleaved by caspases 3 and 7 and has antiapopto-
tic properties [36]. CBT-143-S-F6F7-induced HCC cell
apoptosis may be attributed to the inhibition of these anti-
apoptotic factors. Although a protein array provides a
high-throughput method for identifying the possible pro-
tein targets of CBT-143-S-F6F7, additional studies are re-
quired and are in progress for clarifying the detailed
mechanisms.
To determine the possible active compounds of CBT-
143-S-F6F7, we performed a series of purification and
isolation steps and identified five compounds, oxohinoki-
nin, savinin, deoxypodophyllotoxin, acetyl podophyllo-
toxin, and yatein. Oxohinokinin was isolated from Stellera
chamaejasme L. [37], but no further bioactivity has been
reported. Savinin induced apoptosis in HCT116 colon
carcinoma cells [38]. Deoxypodophyllotoxin has antipro-
liferative, antitumor, antiinflammatory, antioxidant, antial-
lergic, and antiangiogenic activities [39, 40]. Moreover,
deoxypodophyllotoxin induced apoptosis in breast cancer
MDA-MB-231 cells and triggered necroptosis in human
non-small-cell lung cancer NCI-H460 cells [41, 42]. Acetyl
podophyllotoxin is cytotoxic to various cancer cell lines,
such as KB (nasopharyngeal), HF-6 (colon), MCF7
(breast), and PC-3 (prostate) cell lines [43]. Yatein has
anti-proliferative activity [44] and is cytotoxic to various
cancer cell types, such as DLD-1 (human colorectal car-
cinoma), CCRF-CEM (human lymphoblastic leukemia),
HL-60 (human myeloid leukemia), and IMR-32 cells
(human neuroblastoma) [45]. Although some of these
compounds show antitumor activity, evidence of their
antiangiogenic and anti-HCC activities remains elusive.
According to our study results, we first report the anti-
HCC and antiangiogenic activities of CBT-143-S-F6F7
and suggest the anti-HCC and antiangiogenic activities of
these compounds. An additional study for identifying the
active compounds of CBT-143-S-F6F7 is in progress.
Conclusions
CBT-143-S-F6F7, an active ingredient from an extract of
J. chinensis L. var. sargentii Henry, showed antiangio-
genic activity against the tube formation of HUVECs
and in in vivo Matrigel plug and CAM assays. Further-
more, CBT-143-S-F6F7 showed anti-proliferative activity
against different HCC cells. It also repressed the growth
of Huh7 tumors in SCID mice and prolonged the sur-
vival of orthotopic Huh7-tumor-bearing mice. Because
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of its antiangiogenic and anti-HCC activities, CBT-143-
S-F6F7 can potentially be developed as a novel anti-
HCC drug.
Additional file
Additional file 1: Figure S1. Angiogenesis and apoptosis array analysis
of CBT-143-S-F6F7-treated Huh7 cells. (PPT 1587 kb)
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